Radius Health, Inc. (RDUS) Releases Earnings Results, Misses Estimates By $0.03 EPS
Radius Health, Inc. (NASDAQ:RDUS) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03), Briefing.com reports. The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter last year, the firm earned ($1.07) earnings per share.
Shares of Radius Health (NASDAQ:RDUS) traded down $1.29 on Friday, reaching $29.56. 2,824,590 shares of the company’s stock traded hands, compared to its average volume of 954,239.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 150,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were acquired at an average price of $34.97 per share, for a total transaction of $5,245,500.00. Following the purchase, the insider now directly owns 5,113,799 shares of the company’s stock, valued at approximately $178,829,551.03. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 60,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were acquired at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the purchase, the insider now directly owns 5,248,799 shares in the company, valued at $188,851,788.02. The disclosure for this purchase can be found here. Insiders purchased 519,100 shares of company stock worth $17,970,882 in the last 90 days. 15.00% of the stock is currently owned by corporate insiders.
A number of brokerages have recently commented on RDUS. Jefferies Group LLC cut their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Friday. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Finally, Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Radius Health has an average rating of “Hold” and a consensus target price of $51.00.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.